BeiGene Announces Preliminary Phase 2 Results of Tislelizumab in Chinese Patients with Nasopharyngeal Cancer at the 2019 ASCO Annual Meeting
June 01, 2019 09:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, June 01, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces Acceptance of Supplemental Import Drug Application in China for ABRAXANE® in Metastatic Pancreatic Cancer
May 30, 2019 19:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces Acceptance of a Supplemental New Drug Application in China for Tislelizumab in Urothelial Carcinoma
May 30, 2019 19:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 30, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Reports First Quarter 2019 Financial Results
May 09, 2019 16:05 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, May 09, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Announces Phase 1 Long-Term Exposure Data and Results from Structural and Mechanistic Analyses on Tislelizumab at the AACR Annual Meeting
April 01, 2019 16:05 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, April 01, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics
March 06, 2019 07:00 ET
|
BeiGene, LTD.
Ambrx to receive an upfront payment of US$10 million to apply its proprietary Expanded Genetic Code platforms to discover novel biologic drug candidates in this collaboration with BeiGene and is...
BeiGene to Present at Upcoming Investor Conferences
March 04, 2019 07:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass., and BEIJING, China, March 04, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results
February 27, 2019 16:15 ET
|
BeiGene, LTD.
Company to Host Annual Results Conference Call Today at 6:00 p.m. EST and Investor Event in Hong Kong on February 28th at 2:30 p.m. HKT CAMBRIDGE, Mass. and BEIJING, China, Feb. 27, 2019 (GLOBE...
BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference
February 22, 2019 07:00 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Feb. 22, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma
February 19, 2019 16:30 ET
|
BeiGene, LTD.
CAMBRIDGE, Mass. and BEIJING, China, Feb. 19, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...